

6 July 2023

Lisa Banh
ASX Compliance
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Dear Lisa,

Response to ASX Price Query

Regeneus Ltd (ASX:RGS) (**Regeneus** or **Company**) refers to your Price query letter dated 6 July 2023 and provides the following responses.

1. No. The Company is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.
2. Not applicable.
3. The Company has no explanation as to why there has been a price and volume change in the trading of the Company's securities. The Company, however, notes that it is in the advanced negotiation process to merge with Cambium Medical Technologies LLC, as disclosed to ASX on 28 April 2023.
4. The Company confirms that it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
5. The Company confirms that this response has been authorised and approved by Barry Sechos, Chairman, having authority from the Board to respond to ASX on disclosure matters.

Yours sincerely,

Helen Leung
Company Secretary
Regeneus Ltd

Investor Contact

Helen Leung, Corporate Secretary
1300 995 098 helen.leung@regeneus.com